- Home
- SLDB vs CYRX Comparison
SLDB vs CYRX Comparison
Compare SLDB & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLDB | CYRX |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.6M | 419.3M |
| IPO Year | 2017 | 2008 |
Fundamental Metrics
Financial Performance| Metric | SLDB | CYRX |
|---|---|---|
| Price | $7.18 | $10.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $16.36 | $13.31 |
| AVG Volume (30 Days) | ★ 867.5K | 402.7K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.97 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | $8,094,000.00 | ★ $176,177,000.00 |
| Revenue This Year | N/A | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | ★ N/A | $7.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.52 | $5.31 |
| 52 Week High | $8.87 | $11.45 |
Technical Indicators
Market Signals| Indicator | SLDB | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 60.12 |
| Support Level | $5.08 | $9.18 |
| Resistance Level | $7.35 | $11.00 |
| Average True Range (ATR) | 0.41 | 0.40 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 10.22 | 53.59 |
Price Performance
Historical ComparisonAbout SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.